The S-1 prominently features Civitas' successful Phase IIb study for an inhaled formulation of levodopa, a "rescue" treatment for Parkinson's patients.
Civitas Therapeutics has nailed down a substantial $55 million venture round aimed at getting its lead program for Parkinson's through Phase III and onto the market. The Chelsea, MA-based biotech is developing CVT-301, a fast-acting rescue formulation of levodopa that can be self-administered through an inhaler.
Columbia University scientists showed that it is possible to control the size of the blood-brain barrier opening by varying the pressure of an ultrasound beam, a discovery that could herald major breakthroughs in the treatment of neurological diseases.
Austria-based vaccinemaker Affiris announced that its Parkinson's disease vaccine has met its primary endpoint in a small Phase I safety trial of patients receiving two different doses of the jab.
A sublingually delivered thin film strip to treat advanced Parkinson's disease kicked off its Phase II clinical trial following discussions with the FDA, Cynapsus Therapeutics announced July 16.
Using targeted antibodies in the brain, researchers from the University of Pennsylvania have developed a possible treatment for Parkinson's that intercepts disease-causing proteins accumulating in the neurons. In a proof-of-concept study, the team demonstrated that the antibodies prevented pathology and also reversed the effects of the disease in some cases.
President Obama's Brain Initiative awarded millions to University of California researchers to develop mini brain implants that treat Parkinson's disease and epilepsy.
Researchers at Rice University in Texas have developed a new kind of drug delivery particle: a "tunable" virus that releases a treatment only in the presence of not one but two different enzymes that show elevated levels at the site of a tumor.
Civitas Therapeutics announced that its inhaled formulation of levodopa for the treatment of "off episodes" associated with Parkinson's disease met its primary clinical endpoint in a Phase II trial.
Cynapsus Therapeutics' sublingually delivered reformulation of the drug used to treat advanced Parkinson's disease cleared an initial clinical hurdle, the company said April 24.